Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohnʼs Disease

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study

(2016) J. D. Doecke et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

693 Azathioprine Dose Reduction in Inflammatory Bowel Disease Patients on Combination Therapy: A Prospective Study

(2016) Emilie Del Tedesco et al.   GASTROENTEROLOGY

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial

(2016) Takayuki Matsumoto et al.   Journal of Crohns & Colitis

Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease

(2016) Clare Moore et al.   Journal of Crohns & Colitis

PTH-071 A multidisciplinary virtual biologics clinic: is it worthwhile?

(2016) J Duncan et al.   GUT

Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis

(2015) D. Christophorou et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis

(2015) J.-F. Colombel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials

(2015) Jennifer L. Jones et al.   Clinical Gastroenterology and Hepatology

Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy

(2015) Andres J. Yarur et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetics of adalimumab in Crohn’s disease

(2015) David Ternant et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

(2015) Filip Baert et al.   GUT

Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing

(2015) Guillaume Bouguen et al.   INFLAMMATORY BOWEL DISEASES

Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease

(2015) J. R. Goodhand et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Use of azathioprine in IBD: modern aspects of an old drug

(2014) Edouard Louis et al.   GUT

Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD

(2014) Parambir S Dulai et al.   GUT

Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis

(2014) Uri Kopylov et al.   Journal of Crohns & Colitis

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

(2013) R. Panaccione et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Mechanism of allopurinol induced TPMT inhibition

(2013) P.A. Blaker et al.   BIOCHEMICAL PHARMACOLOGY

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease

(2013) W. J. Sandborn et al.   CURRENT MEDICAL RESEARCH AND OPINION

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

(2013) Bella Ungar et al.   GUT

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

(2012) C. Reenaers et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-infliximab antibodies in inflammatory bowel disease

(2012) Lennard Y.W. Lee et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic

(2012) M. Smith et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol

(2012) Melissa A. Smith et al.   Journal of Crohns & Colitis

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

(2010) H. Sokol et al.   GUT

Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease

(2010) Melissa L. Haines et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS